Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2017’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)

The report reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Leishmaniasis (Kala-Azar) therapeutics and enlists all their major and minor projects

The report assesses Leishmaniasis (Kala-Azar) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advinus Therapeutics Ltd

BioLingus AG

Daiichi Sankyo Company Ltd

iCo Therapeutics Inc.

Laboratorios LETI SL

ManRos Therapeutics

Matinas BioPharma Holdings Inc

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leishmaniasis (Kala-Azar) - Overview

Leishmaniasis (Kala-Azar) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Leishmaniasis (Kala-Azar) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development

Advinus Therapeutics Ltd

BioLingus AG

Daiichi Sankyo Company Ltd

iCo Therapeutics Inc.

Laboratorios LETI SL

ManRos Therapeutics

Matinas BioPharma Holdings Inc

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Leishmaniasis (Kala-Azar) - Drug Profiles

(gentamicin sulfate + paromomycin sulfate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

candicidin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDRI-99288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNF-6702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hypoestoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon gamma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KVH-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPC-1161B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-MAPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-015-2344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Visceral Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Visceral Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Visceral Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CD206 for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LHR1 for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

visceral leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leishmaniasis (Kala-Azar) - Dormant Projects

Leishmaniasis (Kala-Azar) - Discontinued Products

Leishmaniasis (Kala-Azar) - Product Development Milestones

Featured News & Press Releases

Nov 28, 2016: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program

Aug 08, 2016: A single compound could treat three parasitic diseases

Dec 15, 2015: U.S. Issues Patent on Corifungin

Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program

Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions

Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients

Feb 26, 2013: National Institutes of Health Supports Acea’s Research

Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee

Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis

Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS

Jul 01, 2011: FDA issues orphan-drug designation to Corifungin

Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status

Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC

Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by Advinus Therapeutics Ltd, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by BioLingus AG, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by iCo Therapeutics Inc., H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by Laboratorios LETI SL, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by ManRos Therapeutics, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by Nanomerics Ltd, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by Novartis AG, H1 2017

Leishmaniasis (Kala-Azar) – Pipeline by Oblita Therapeutics BVBA, H1 2017

Leishmaniasis (Kala-Azar) – Dormant Projects, H1 2017

Leishmaniasis (Kala-Azar) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Leishmaniasis (Kala-Azar) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports